NCT06298799Unknown不适用
RETRO-PROSPECTIVE OPEN STUDY TO ASSES GENETIC VARIABILITY AS A BASIS FOR PREDICTION OF THE RESPONSE TO GLP1 TREATMENT
GENGE1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2023年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Genetic variants and miRNA expressions associated with changes in BMI.
研究概览
简要总结
The goal of this retrospective study is to assess whether a selection of genetic variants may allow us to identify individuals who will have a satisfactory response after GLP-1 treatment in terms of weight loss, sugar level reduction, and adverse events.
Participants will The study consists of a single visit at the diabetes unit clinic at the involved study sites. The following will be performed for every subject at the study screening enrollment visit:
- Informed consent
- Study eligibility (Inclusion / Exclusion criteria)
- Collection of demographic data (age (date of birth), gender, ethnic origin)
- General and T2DM medical history review (per subject file)
- Concomitant medication review (at enrollment)
- Physical attributes (Body Weight, Height, BMI)
- Allocation to study cohort and study subgroup
- Saliva and blood collection for genetic tests
- Self-reported questionnaire for Ozempic (Semaglutide) experience
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
盲法说明
no masking
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosed with type 2 diabetes (for participant in Cohort A) or Obese (for participant in Cohort B) and treated with Ozempic (Semaglutide) S.C. injection for at least 24 weeks.
- •Subject is male/female between 18 to 80 years old (both inclusive) at the time of enrollment.
- •Subject BMI above 30 kg/m2 at treatment initiation.
- •Subject does not belong to any vulnerable population, is willing and able to provide written informed consent prior to any study procedure.
- •Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol.
排除标准
- •Subject falls under contraindications to Ozempic (Semaglutide) label
- •Subject known or suspected for hypersensitivity to any GLP-1RA or related products, or allergic constitution
- •Subjects suffers from any other condition affecting body weight.
- •Subject with history of chronic or acute pancreatitis
- •Subject have a history of a major cardiovascular and/or cerebrovascular disease within the 6 months before screening.
- •Presence or history of malignant neoplasm within 5 years prior to screening day.
- •Subject suffers from any renal impairment (Cr > 2 mg/dl).
- •Subject suffers from any impaired hepatic function (ALT, AST or GGT 2-fold higher than normal upper limit).
- •Any disorder, which in the investigator's opinion might jeopardize patient's safety or compliance with the protocol.
- •Subject is a female who is pregnant, breastfeeding or intends to become pregnant or is of child bearing potential without medically acceptable methods of contraception.
- •Participation in another clinical study in prior 4 weeks.
结局指标
主要结局
Genetic variants and miRNA expressions associated with changes in BMI.
时间窗: 12 months
Identify genetic variants and miRNA expressions that affects the response to GLP-1 treatment associated with changes in BMI.
次要结局
- Genetic variants and miRNA expressions associated with changes in A1c.(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AMLLeukemia, Myeloid, AcuteNCT06580106Wake Forest University Health Sciences50
暂停
3 期
Efficacy of Ovarian Stimulation Based on FSHR Genotype StatusSterilityNCT00749853Medical University of Vienna165
进行中（未招募）
2 期
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's DiseaseAlzheimer DiseaseNCT04840979Columbia University107
已完成
不适用
Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast CancerBreast CancerNCT04354675Case Comprehensive Cancer Center35
已完成
4 期
Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of ClopidogrelInfluence of Genotype of Drug Metabolizing Enzyme or Transporter on the Pharmacokinetics/Pharmacodynamics of ClopidogrelInfluence of Aspirin on the Pharmacokinetics/Pharmacodynamics of ClopidogrelNCT01503658Seoul National University Hospital18